Concerns about the operational definition of remission in 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus

We have read the recently published update of the EULAR recommendations for the management of systemic lupus erythematosus (SLE) recommendations1 with great interest. While we greatly appreciate the effort made by the panel of experts, we would like to add our own comments with regards treatment objectives and the definition of remission.

Remission as suggested in figure 11 would be defined as systemic lupus erythematosus disease activity index (SLEDAI)=0 with no use of corticosteroids at all. However, although we are aware of the lack a universal definition for remission for SLE,2 we believe this view of remission is too stringent, given that it should include remission of both a clinical and serological nature. Working within of this definition poses doubts as to the amount of effort that would have to be made in order to achieve remission in our SLE patients. For example, in the scenario of patients with no active clinical lupus but with hypocomplementemia of positive native DNA (serologically active, SLEDAI=4), a common occurrence in daily clinical practice, should we even use belimumab, to get a ‘complete remission’ as defined in the 2009 update of EULAR expert’s panel recommendations?

Several groups have proposed a diverse set of remission criteria for SLE and the creation of an international task force has led to the DORIS group proposal,3 in which for two levels of remission, we believe this view of remission is too stringent, given that it should include remission of both a clinical and serological nature. Working within of this definition poses doubts as to the amount of effort that would have to be made in order to achieve remission in our SLE patients. For example, in the scenario of patients with no active clinical lupus but with hypocomplementemia of positive native DNA (serologically active, SLEDAI=4), a common occurrence in daily clinical practice, should we even use belimumab, to get a ‘complete remission’ as defined in the 2009 update of EULAR expert’s panel recommendations?

In summary, we suggest that in order to avoid confusion, the definition ‘SLEDAI=0’ in figure 1 of the document should be changed for ‘clinical SLEDAI=0’.

Íñigo Rua Figueroa, Celia Erausquin
Rheumatology, Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de Gran Canaria, Spain

Correspondence to Dr Íñigo Rua Figueroa, Rheumatology, Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de Gran Canaria 35020, Spain; irufer@gobiernodecanarias.org

Contributors Both authors have contributed to the ideas, contents and redaction of the letter.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; internally peer reviewed.

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

To cite Rua Figueroa I, Erausquin C. Ann Rheum Dis 2020;79:e131.

Received 25 May 2019
Accepted 30 May 2019
Published Online First 5 June 2019

http://dx.doi.org/10.1136/annrheumdis-2019-215810


ORCID iD
Íñigo Rua Figueroa http://orcid.org/0000-0002-7894-1690

REFERENCES